GlaxoSmithKline Pharmaceuticals Ltd Share Price

Overview

GlaxoSmithKline Pharmaceuticals Ltd share price is currently ₹2,678.30, up by ₹12.60 (0.47%) from its previous closing price of ₹2,665.70. The share price has gained 9.19% over the past month and gained 2.63% over the past year. The stock's 52-week low and high are ₹2,048.50 and ₹2,843.42, respectively. GlaxoSmithKline Pharmaceuticals Ltd has a market capitalisation of ₹ 45,550.00 Cr. The share price was last updated on 18 Aug 2026, 11:24 AM IST.

GlaxoSmithKline Pharmaceuticals Ltd

GLAXO

₹0.00

₹12.60

0.47%

Healthcare

₹0.00(%)1D

Updated: 18 Aug 2026, 11:24:05 am IST

Market Data

Open Price

₹2,680.26

Prev. Close

₹2,665.70

₹2,671.31

Day Low

₹2,692.07

Day High

₹2,048.50

52 Week Low

₹2,843.42

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

42.48

Sector PE

42.16

PB Ratio

19.87

Sector PB

5.84

EPS

63.05

Dividend Yield

2.50

Today's Volume

10.450 K

5 Day Avg. Volume

62.652 K

PEG Ratio

3.63

Market Cap.

₹ 45,550.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 570% at ₹57/Share	29-May-2026	29-May-2026
DividendsFinal Dividend of 420% at ₹42/Share	30-May-2025	30-May-2025
DividendsInterim Dividend of 120% at ₹12/Share	07-Nov-2024	07-Nov-2024

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
SBI Midcap Fund - Regular Plan - Growth	12.00 Lac	12.00 Lac no change
Kotak Large & Midcap Fund - Growth	11.00 Lac	11.00 Lac no change
Nippon India Pharma Fund - Growth	9.13 Lac	9.29 Lac (1.71%)
Nippon India Growth Mid Cap Fund - Growth Option	5.59 Lac	5.59 Lac no change
SBI Dividend Yield Fund - Regular Plan - Growth	4.50 Lac	4.50 Lac no change

Show all holdings

About GlaxoSmithKline Pharmaceuticals Ltd 👋

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.